Eli Lilly's GLP-1 Obesity Drug Shows Growing Promise in Phase 3 Trials

Eli Lilly has reported positive Phase 3 clinical trial results for its investigational obesity treatment, Retatrutide, with its latest GLP-1 drug showing significant promise as a powerful weapon in the fight against obesity.